Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Shi-yu Luo"'
Publikováno v:
Journal of Cardiovascular Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fa3284eff9be346e16ce2140011887e
https://doi.org/10.1097/fjc.0000000000001322
https://doi.org/10.1097/fjc.0000000000001322
Publikováno v:
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020)
Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020)
Objective. We examined the effects of acupotomy on the PI3K/Akt signaling pathway to elucidate the mechanism of action of acupotomy on articular chondrocyte apoptosis among rabbits with knee osteoarthritis (KOA). Methods. New Zealand rabbits were ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4359690f90416447f58c4116e9814c1f
https://doi.org/10.1155/2020/4241917
https://doi.org/10.1155/2020/4241917
Publikováno v:
Journal of cardiovascular pharmacology. 80(4)
Inositol 1, 4, 5-trisphosphate (IP3) signaling-mediated calcium release drives the contraction of vascular smooth muscles and hence regulates blood vessel volume and blood pressure. Melatonin supplementation has been suggested to be beneficial for hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::606325dc104ba53e774f18639f44071f
https://pubmed.ncbi.nlm.nih.gov/35881446
https://pubmed.ncbi.nlm.nih.gov/35881446
Autor:
Yang Hui Huang, Sung Han Hsiao, Chung-Pu Wu, Yan Qing Li, Shi Yu Luo, Chiun Wei Huang, Ching Ya Su, Chia Hung Hsieh
Publikováno v:
Biochemical Pharmacology. 92:567-576
CUDC-101 is the first small-molecule inhibitor designed to simultaneously inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and histone deacetylase (HDAC) in cancer cells. Recently, in its first in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f483ddb5741a569910e1325b5d93d0b
https://doi.org/10.1016/j.bcp.2014.10.003
https://doi.org/10.1016/j.bcp.2014.10.003
Autor:
Chiun Wei Huang, Chia Hung Hsieh, Yan Qing Li, Yang Hui Huang, Ching Ya Su, Sheng-Chieh Hsu, Shi Yu Luo, Sung Han Hsiao, Chung-Pu Wu
Publikováno v:
Molecular pharmaceutics. 12(11)
The overexpression of the serine/threonine specific polo-like kinase 1 (Plk1) is associated with poor prognosis in many types of cancer. Consequently, Plk1 has emerged as a valid therapeutic target for anticancer drug design. Volasertib is a potent i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4c31b5bf5cac4c7e4498d7a14f2fd7a
https://pubmed.ncbi.nlm.nih.gov/26412161
https://pubmed.ncbi.nlm.nih.gov/26412161
Autor:
Sung Han Hsiao, Yang Hui Huang, Wei Cherng Tuo, Shi Yu Luo, Chia Hung Hsieh, Yan Qing Li, Ching Ya Su, Chung-Pu Wu
Publikováno v:
Molecular pharmaceutics. 11(10)
Polo-like kinase 1 (Plk1) is a serine/threonine kinase involved in the regulation of mitosis and is overexpressed in many tumor types. Inhibition of Plk1 leads to cell cycle arrest, onset of apoptosis, and cell death, thus Plk1 has emerged as an impo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5355633514f423861882d6d8f43ac93
https://pubmed.ncbi.nlm.nih.gov/25192198
https://pubmed.ncbi.nlm.nih.gov/25192198
Autor:
Yang-Hui Huang, Shi-Yu Luo, Sung-Han Hsiao, Cheng-Ting Chiang, Chung-Pu Wu, Wei-Cherng Tuo, Yan-Qing Li, Ching-Ya Su
Publikováno v:
Journal of Cancer Research Updates. 3
The polo-like kinase 1 (Plk1) is one of the key regulators in cell cycle progression. Plk1 is overexpressed in many types of cancer and promotes the proliferation of cancer cells. Inhibition of Plk1 activity induces G2/M cell cycle arrest and reduces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a271a074626c09828ac81f4445d5d07
https://doi.org/10.6000/1929-2279.2014.03.02.5
https://doi.org/10.6000/1929-2279.2014.03.02.5
Autor:
Shi Yu Luo, 羅仕瑜
102
The overexpression of the serine/threonine specific polo-like kinase 1 (Plk1) has been detected in various types of cancer, and thus has fast become an attractive therapeutic target for cancer therapy. Plk1 inhibitors BI 2536, volasertib and
The overexpression of the serine/threonine specific polo-like kinase 1 (Plk1) has been detected in various types of cancer, and thus has fast become an attractive therapeutic target for cancer therapy. Plk1 inhibitors BI 2536, volasertib and
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/48402034791397339617
Autor:
Yan-Qing Li, Hsing-Wen Cheng, Sung-Han Hsiao, Hong-May Sim, Yang-Hui Huang, Shi-Yu Luo, Suresh V. Ambudkar, Chung-Pu Wu, Wei-Cherng Tuo
The overexpression of the serine/threonine specific Polo-like kinase 1 (Plk1) has been detected in various types of cancer, and thus has fast become an attractive therapeutic target for cancer therapy. BI 2536 is the first selective inhibitor of Plk1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e608a341ad537f51598ae50fc4005a0
https://europepmc.org/articles/PMC3791609/
https://europepmc.org/articles/PMC3791609/
Autor:
Shi-Yu, Luo
Publikováno v:
2015 Seventh International Conference on Measuring Technology & Mechatronics Automation; 2015, p346-349, 4p